Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (tysabri®) Dosing: NOVA Phase IIIb Extension Study (part 2)
Neurology and Therapy（2024）
关键词
Extended interval dosing,Intravenous,Multiple sclerosis,Natalizumab,NOVA,Patient preference,Subcutaneous
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要